Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study

被引:9
作者
Chen ZhenPing [1 ]
Li PeiJing [1 ]
Li Gang [1 ]
Tang Ling [1 ]
Zhen YingZi [1 ]
Wu XinYi [1 ]
Cheng XiaoLing [1 ]
Hung Luke Koon [2 ]
Blanchette Victor S [3 ]
Poon ManChiu [4 ]
Ding QiuLan [5 ]
Wu RunHui
机构
[1] Hematology Oncology Center, Beijing Children’s Hospital, Capital Medical University, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Ministry of Education, Beijing 100045, China
[2] Department of Medicine, Pediatrics and Oncology, and Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program, University of Calgary, Foothills Hospital and Calgary Health Region, Calgary, Alberta, T2N2T9, Canada
[3] Department of Pediatrics and Laboratory Medicine, and Hemophilia Clinic, Children’s Hospital of Eastern Ontario and University of Ottawa, Ottawa, Ontario, K1H 8L1, Canada
[4] Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China
[5] Department of Pediatrics and Child Health Evaluative Sciences, Division of Hematology/Oncology, Research Institute, Hospital for Sick Children, University of Toronto, Toronto, Ontario, M5G 1X8, Canada
关键词
Boys; Factor VIII; Hemophilia A; Pharmacokinetics;
D O I
暂无
中图分类号
R554.1 [];
学科分类号
1002 ; 100201 ;
摘要
Background: Although much attention has been paid to the pharmacokinetics (PKs) of different factor VIII (FVIII) concentrates in persons with hemophilia A (HA), limited information is available in young boys with severe HA. In this study, we aimed to assess the PK parameters of FVIII products in boys with severe HA in China.Methods: A total of 36 boys (plasma-derived [pd]-FVIII,n = 15; recombinant [r] FVIII,n = 21) were enrolled between January 2015 and May 2016 in Beijing Children’s Hospital. PK characteristics of FVIII products were studied according to a reduced 4-sampling time point design (1 h, 9 h, 24 h, and 48 h postinfusion).Results: The mean FVIII half-life (t1/2) was 10.99 ± 3 .45 h (range 5.52- 20.02 h), the meanin vivo recovery (IVR) was 2.01 ± 0.42 IU/dl per IU/kg (range 1.24–3.02 IU/dl per IU/kg) and mean clearance (CL) of FVIII is 4.34 ± 1.58 ml·kg?1·h?1 (range 2.29–7.90 ml·kg?1·h?1). We also analyzed the influence of several parameters that potentially modulate FVIII PK. The age was closely associated with FVIII half-life (R2 = 0.32,P< 0.01). The t1/2 of FVIII increased by 0.59 h per year. Besides age, von Willebrand factor antigen (VWF:Ag) also was associated with FVIII half-life (R2 = 0.52,P< 0.01). Patients with blood Group O had a shorter FVIII half-life than patients with non-O blood group (9.40 ± 0.68 h vs. 12.3 ± 0.79 h,t = 2.70,P= 0.01). The FVIII IVR correlated with age (R2 = 0.21,P< 0.01) and VWF:Ag level (R2 = 0.28,P< 0.01). CL rates were faster in young patients and in those with low-VWF:Ag levels. CL rates of FVIII are higher in blood Group O versus non-blood Group O persons (5.02 ± 0.38 vs. 4.00 ± 0.32 ml·kg?1·h?1,t= 2.53,P= 0.02).Conclusions: Chinese boys with severe HA have similar PK values to other ethnic groups and large differences in FVIII PK between individual patients. Age, blood group, and VWF:Ag levels are important determining factors for FVIII CL.
引用
收藏
页码:1780 / 1785
页数:6
相关论文
共 50 条
  • [41] Long-term course of anti-factor VIII antibody in patients with hemophilia A at a single center
    Yoo, Ki Young
    Joo, Sang Chun
    Choi, Yong Mook
    [J]. BLOOD RESEARCH, 2016, 51 (01) : 37 - 43
  • [42] Bleeds and imaging scoring scales in relation to pharmacokinetics of coagulation factor VIII in Chinese pediatric patients with severe hemophilia A
    Huang, Kun
    Chen, Zhenping
    Gang, Li
    Zhen, Yingzi
    Wu, Xinyi
    Zhang, Ningning
    Wu, Runhui
    [J]. THROMBOSIS RESEARCH, 2020, 193 : 83 - 85
  • [43] Oxidation of factor VIII increases its immunogenicity in mice with severe hemophilia A
    Peyron, Ivan
    Dimitrov, Jordan D.
    Delignat, Sandrine
    Gangadharan, Bagirath
    Srivastava, Alok
    Kaveri, Srinivas V.
    Lacroix-Desmazes, Sebastien
    [J]. CELLULAR IMMUNOLOGY, 2018, 325 : 64 - 68
  • [44] Factor VIII half-life and clinical phenotype of severe hemophilia A
    van Dijk, Karin
    van der Bom, Johanna G.
    Lenting, Peter J.
    de Groot, Philip G.
    Mauser-Bunschoten, Eveline P.
    Roosendaal, Goris
    Grobbee, Diederick E.
    van den Berg, H. Marijke
    [J]. HAEMATOLOGICA, 2005, 90 (04) : 494 - 498
  • [45] Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review
    Hassan, S. .
    Cannavo, A.
    Gouw, S. C.
    Rosendaal, F. R.
    van der Bom, J. G.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2018, 16 (06) : 1055 - 1068
  • [46] Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A
    Powell, J. S.
    Nugent, D. J.
    Harrison, J. A.
    Soni, A.
    Luk, A.
    Stass, H.
    Gorina, E.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (02) : 277 - 283
  • [47] Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A
    Collins, P. W.
    Blanchette, V. S.
    Fischer, K.
    Bjorkman, S.
    Oh, M.
    Fritsch, S.
    Schroth, P.
    Spotts, G.
    Astermark, J.
    Ewenstein, B.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (03) : 413 - 420
  • [48] Antibody response to recombinant human coagulation factor VIII in a new rat model of severe hemophilia A
    Lovgren, K. M.
    Sondergaard, H.
    Skov, S.
    Weldingh, K. N.
    Tranholm, M.
    Wiinberg, B.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2016, 14 (04) : 747 - 756
  • [49] Identification of seven novel mutations in the factor VIII gene in 18 unrelated Chinese patients with hemophilia A
    Hua Bao-lai
    Yan Zhen-yu
    Liang Yan
    Yan Mei
    Fan Lian-kai
    Li Kui-xing
    Xiao Bai
    Liu Jing-zhong
    Zhao Yong-qiang
    [J]. CHINESE MEDICAL JOURNAL, 2010, 123 (03) : 305 - 310
  • [50] A retrospective single-center study on the effectiveness and tolerability of emicizumab in patients with hemophilia a with and without inhibitors
    Ahmad, Sheikh Bilal
    Amin, Asifa
    Rohi, Malik
    Muzaffar, Sarwat
    Fahad, Sheikh
    [J]. EXPERT REVIEW OF HEMATOLOGY, 2025, 18 (03) : 275 - 281